

7 Literaturverzeichnis

- Affolter, J. T., D. E. Newby, et al. (2002). "No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans." Br J Clin Pharmacol **54**(6): 617-21.
- Aiyar, N., B. Guida, et al. (2004). "Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays." Peptides **25**(8): 1339-47.
- Ames, R. S., H. M. Sarau, et al. (1999). "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14." Nature **401**(6750): 282-6.
- Arakawa, K. and H. Maruta (1980). "Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'." Nature **288**(5792): 705-6.
- Azaryan, A., N. Barkhudaryan, et al. (1985). "Action of brain cathepsin B, cathepsin D, and high-molecular-weight aspartic proteinase on angiotensins I and II." Neurochem Res **10**(11): 1525-32.
- Azuma, T., G. Pals, et al. (1989). "Human gastric cathepsin E. Predicted sequence, localization to chromosome 1, and sequence homology with other aspartic proteinases." J Biol Chem **264**(28): 16748-53.
- Behm, D. J., C. L. Herold, et al. (2004). "Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors." Eur J Pharmacol **492**(2-3): 113-6.
- Bennett, R. T., R. D. Jones, et al. (2004). "Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries." Thorax **59**(5): 401-7.
- Berg, T., H. Schoyen, et al. (1992). "Characterization of a new kallikrein-like enzyme (KLP-S3) of the rat submandibular gland." Biochem J **281** (Pt 3): 819-28.
- Bohm, F. and J. Pernow (2002). "Urotensin II evokes potent vasoconstriction in humans in vivo." Br J Pharmacol **135**(1): 25-7.
- Bottrill, F. E., S. A. Douglas, et al. (2000). "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries." Br J Pharmacol **130**(8): 1865-70.
- Bousette, N., L. Patel, et al. (2004). "Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta." Atherosclerosis **176**(1): 117-23.
- Brkovic, A., A. Hattenberger, et al. (2003). "Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay." J Pharmacol Exp Ther **306**(3): 1200-9.
- Butler, J. E., W. C. Hamilton, et al. (1982). "Detection and partial characterization of two bovine pregnancy-specific proteins." Biol Reprod **26**(5): 925-33.
- Camarda, V., A. Rizzi, et al. (2002). "Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents." Naunyn Schmiedebergs Arch Pharmacol **365**(2): 141-9.
- Changaris, D. G., J. J. Miller, et al. (1986). "Angiotensin II generated by a human renal carboxypeptidase." Biochem Biophys Res Commun **138**(2): 573-9.
- Chartrel, N., J. Leprince, et al. (2004). "Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord." J Neurochem **91**(1): 110-8.
- Chatenet, D., C. Dubessy, et al. (2004). "Structure-activity relationships and structural conformation of a novel urotensin II-related peptide." Peptides **25**(10): 1819-30.

- Cheung, B. M., R. Leung, et al. (2004). "Plasma concentration of urotensin II is raised in hypertension." J Hypertens **22**(7): 1341-4.
- Coulouarn, Y., I. Lihmann, et al. (1998). "Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord." Proc Natl Acad Sci U S A **95**(26): 15803-8.
- Davenport, A. P. and J. J. Maguire (2000). "Urotensin II: fish neuropeptide catches orphan receptor." Trends Pharmacol Sci **21**(3): 80-2.
- Douglas, S. A., A. C. Sulpizio, et al. (2000). "Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey." Br J Pharmacol **131**(7): 1262-74.
- Douglas, S. A., L. Tayara, et al. (2002). "Congestive heart failure and expression of myocardial urotensin II." Lancet **359**(9322): 1990-7.
- Dorer, F. E., K. E. Lentz, et al. (1978). "A comparison of the substrate specificities of cathepsin D and pseudorenin." J Biol Chem **253**(9): 3140-2.
- El Amiri, B., N. Melo de Sousa, et al. (2003). "Double radial immunodiffusion as a tool to identify pregnancy-associated glycoproteins in ruminant and nonruminant placentae." Theriogenology **59**(5-6): 1291-301.
- Faust, P. L., S. Kornfeld, et al. (1985). "Cloning and sequence analysis of cDNA for human cathepsin D." Proc Natl Acad Sci U S A **82**(15): 4910-4.
- Flohr, S., M. Kurz, et al. (2002). "Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II." J Med Chem **45**(9): 1799-805.
- Gardiner, S. M., J. E. March, et al. (2004). "Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response." Br J Pharmacol **143**(3): 422-30.
- Gardiner, S. M., J. E. March, et al. (2001). "Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats." Br J Pharmacol **132**(8): 1625-9.
- Genest, J., W. Nowaczynski, et al. (1975). "Aldosterone and renin in essential hypertension." Can Med Assoc J **113**(5): 421-31.
- Gibson, A. (1987). "Complex effects of Gillichthys urotensin II on rat aortic strips." Br J Pharmacol **91**(1): 205-12.
- Grieco, P., A. Carotenuto, et al. (2002). "Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues." Bioorg Med Chem **10**(12): 3731-9.
- Haas, E., L. Lewis, et al. (1989). "Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs. Activation of proenzyme III to enzyme III by cathepsin G." Am J Hypertens **2**(9): 708-14.
- Hassan, G. S., F. Chouiali, et al. (2003). "Effect of human urotensin-II infusion on hemodynamics and cardiac function." Can J Physiol Pharmacol **81**(2): 125-8.
- Herold, C. L., D. J. Behm, et al. (2003). "The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors." Br J Pharmacol **139**(2): 203-7.
- Hillier, C., C. Berry, et al. (2001). "Effects of urotensin II in human arteries and veins of varying caliber." Circulation **103**(10): 1378-81.

- Ideishi, M., M. Sasaguri, et al. (1990). "Angiotensin-converting activity of tissue kallikrein." *Nephron* **55 Suppl 1**: 62-4.
- Itoh, H., Y. Itoh, et al. (1987). "Contraction of major artery segments of rat by fish neuropeptide urotensin II." *Am J Physiol* **252**(2 Pt 2): R361-6.
- Katano, Y., A. Ishihata, et al. (2000). "Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries." *Eur J Pharmacol* **402**(1-2): R5-7.
- Kelly, R. A., J. L. Balligand, et al. (1996). "Nitric oxide and cardiac function." *Circ Res* **79**(3): 363-80.
- Kinney, W. A., H. R. Almond Jr, et al. (2002). "Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model." *Angew Chem Int Ed Engl* **41**(16): 2940-4.
- Klickstein, L. B., C. E. Kaempfer, et al. (1982). "The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G." *J Biol Chem* **257**(24): 15042-6.
- Klose, J. and U. Kobalz (1995). "Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome." *Electrophoresis* **16**(6): 1034-59.
- Krieger, T. J. and V. Y. Hook (1992). "Purification and characterization of a cathepsin D protease from bovine chromaffin granules." *Biochemistry* **31**(17): 4223-31.
- Kuster, B., A. P. Hunter, et al. (1998). "Structural determination of N-linked carbohydrates by matrix-assisted laser desorption/ionization-mass spectrometry following enzymatic release within sodium dodecyl sulphate-polyacrylamide electrophoresis gels: application to species-specific glycosylation of alpha1-acid glycoprotein." *Electrophoresis* **19**(11): 1950-9.
- Li, L., W. J. Yuan, et al. (2004). "Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart." *Acta Pharmacol Sin* **25**(11): 1444-9.
- Lochnit, G. and R. Geyer (2004). "An optimized protocol for nano-LC-MALDI-TOF-MS coupling for the analysis of proteolytic digests of glycoproteins." *Biomed Chromatogr* **18**(10): 841-8.
- MacLean, M. R., D. Alexander, et al. (2000). "Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat." *Br J Pharmacol* **130**(2): 201-4.
- Maguire, J. J., R. E. Kuc, et al. (2000). "Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1." *Br J Pharmacol* **131**(3): 441-6.
- Mansur, H. S., R. L. Orefice, et al. (2005). "Biomaterial with chemically engineered surface for protein immobilization." *J Mater Sci Mater Med* **16**(4): 333-40.
- Matsushita, M., M. Shichiri, et al. (2001). "Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues." *J Hypertens* **19**(12): 2185-90.
- McMaster, D., Y. Kobayashi, et al. (1986). "Characterization of the biologically and antigenically important regions of urotensin II." *Proc West Pharmacol Soc* **29**: 205-8.
- Mori, M. and M. Fujino (2004). "Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain." *Peptides* **25**(10): 1815-8.
- Mori, M., T. Sugo, et al. (1999). "Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)." *Biochem Biophys Res Commun* **265**(1): 123-9.
- Nothacker, H.-P. and O. Civelli (2003). Characterization of a novel urotensin II precursor: urotensin II B (U2B). *EMBL/GenBank/DDBJ databases*. **Entry: Q76510**.
- Packer, N. H., W. I. MR, et al. (1996). "Characterization of human plasma glycoproteins separated by two-dimensional gel electrophoresis." *Biotechnology (N Y)* **14**(1): 66-70.

- Pearson, D., J. E. Shively, et al. (1980). "Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes." Proc Natl Acad Sci U S A **77**(8): 5021-4.
- Richards, A. M. and C. Charles (2004). "Urotensin II in the cardiovascular system." Peptides **25**(10): 1795-802.
- Rossowski, W. J., B. L. Cheng, et al. (2002). "Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists." Eur J Pharmacol **438**(3): 159-70.
- Russell, F. D., P. Kearns, et al. (2004). "Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro." J Pharmacol Exp Ther **310**(1): 209-14.
- Russell, F. D., D. Meyers, et al. (2003). "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure." Am J Physiol Heart Circ Physiol **285**(4): H1576-81.
- Sauzeau, V., E. Le Mellionnec, et al. (2001). "Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase." Circ Res **88**(11): 1102-4.
- Shenouda, A., S. A. Douglas, et al. (2002). "Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma." J Histochem Cytochem **50**(7): 885-9.
- Skeggs, L. T., F. E. Dorer, et al. (1976). "The biochemistry of the renin-angiotensin system and its role in hypertension." Am J Med **60**(6): 737-48.
- Skeggs, L. T., Jr., W. H. Marsh, et al. (1954). "The purification of hypertension I." J Exp Med **100**(4): 363-70.
- Sogawa, K., Y. Fujii-Kuriyama, et al. (1983). "Primary structure of human pepsinogen gene." J Biol Chem **258**(8): 5306-11.
- Stirrat, A., M. Gallagher, et al. (2001). "Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries." Am J Physiol Heart Circ Physiol **280**(2): H925-8.
- Strausberg, R. L., E. A. Feingold, et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc Natl Acad Sci U S A **99**(26): 16899-903.
- Sugo, T., Y. Murakami, et al. (2003). "Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain." Biochem Biophys Res Commun **310**(3): 860-8.
- Szafranska, B., M. Majewska, et al. (2004). "N-glycodiversity of the Pregnancy-Associated Glycoprotein family (PAG) produced in vitro by trophoblast and trophectoderm explants during implantation, placentation and advanced pregnancy in the pig." Reprod Biol **4**(1): 67-89.
- Szafranska, B., S. Xie, et al. (1995). "Porcine pregnancy-associated glycoproteins: new members of the aspartic proteinase gene family expressed in trophectoderm." Biol Reprod **53**(1): 21-8.
- Takahashi, K., K. Totsune, et al. (2003). "Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II." Peptides **24**(2): 301-6.
- Takahashi, K., K. Totsune, et al. (2001). "Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells." Peptides **22**(7): 1175-9.
- Thiemann, J., J. Jankowski, et al. (2004). "Principle and applications of the protein-purification-parameter screening system." J Chromatogr A **1043**(1): 73-80.

- Thompson, J. P., P. Watt, et al. (2003). "A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study." Anesth Analg **97**(5): 1501-3.
- Totsune, K., K. Takahashi, et al. (2003). "Increased plasma urotensin II levels in patients with diabetes mellitus." Clin Sci (Lond) **104**(1): 1-5.
- Totsune, K., K. Takahashi, et al. (2001). "Role of urotensin II in patients on dialysis." Lancet **358**(9284): 810-1.
- Urade, R., T. Oda, et al. (1997). "Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-Leu (QEDL) motifs of microsomal ER-60 protease." J Biochem (Tokyo) **122**(4): 834-42.
- Urata, H., A. Kinoshita, et al. (1990). "Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart." J Biol Chem **265**(36): 22348-57.
- Wilkinson, I. B., J. T. Affolter, et al. (2002). "High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man." Cardiovasc Res **53**(2): 341-7.
- Zhang, A. Y., Y. F. Chen, et al. (2003). "Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney." Am J Physiol Renal Physiol **285**(4): F792-8.
- Zhu, Y. Z., Z. J. Wang, et al. (2004). "Urotensin II causes fatal circulatory collapse in anesthetized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile." Am J Physiol Heart Circ Physiol **286**(3): H830-6. Mori, M., T. Sugo, et al. (1999). "Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)." Biochem Biophys Res Commun **265**(1): 123-9.